EDT

Texas Capital Bancshares, Inc. Announces Date for Q1 2024 Operating Results

Retrieved on: 
Thursday, April 4, 2024
Capital Bank, PIN, Texas Capital Bank, EDT

DALLAS, April 04, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2024 before market on Thursday, April 18, 2024.

Key Points: 
  • DALLAS, April 04, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2024 before market on Thursday, April 18, 2024.
  • Executive management will host a conference call and webcast to discuss first quarter 2024 operating results on Thursday, April 18, 2024, at 9:00 a.m. EDT.
  • Alternatively, participants may call 833.470.1428 and use the access code 809576 at least fifteen minutes prior to the call to join through an operator.
  • This replay will be available until May 16, 2024.

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

O-I Glass Announces First Quarter 2024 Earnings Conference Call and Webcast

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Glass, EDT, OI, News

PERRYSBURG, Ohio, April 03, 2024 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (NYSE: OI) has scheduled its first quarter 2024 conference call and webcast for Wednesday, May 1, 2024, at 8 a.m. EDT.

Key Points: 
  • PERRYSBURG, Ohio, April 03, 2024 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (NYSE: OI) has scheduled its first quarter 2024 conference call and webcast for Wednesday, May 1, 2024, at 8 a.m. EDT.
  • The Company’s news release for the first quarter 2024 earnings will be issued after the market closes on Tuesday, April 30.
  • Earnings presentation materials will also be posted on the O-I website, www.o-i.com/investors , when the earnings news release is issued.
  • The webcast will be archived at www.o-i.com/investors until May 2025.

INVNT GROUP™ Presents Mad Dog Jones’ Newest NFT Collection 'Fallen Gravity': Cyberpunk Art and Star Songs Collide in collaboration with INVNT.ATOM™, Artemis Music Entertainment, and Nifty Gateway

Retrieved on: 
Wednesday, April 3, 2024
Open Edition, Apollo program, Limited Edition, Algorithm, Nifty Gateway, Music, Blockchain, Star Music, International Space Station, History, EDT, NFT, Sale, Mission control center, Orbit, Collection, Non-fungible token, Telemetry, Senior producer, Extraterrestrial life, ISS, Star Song Communications, Gravity, Dream, Creativity, Communications satellite

On his inspiration for the project, Mad Dog Jones comments, “Fallen Gravity is about drifting into the unknown.

Key Points: 
  • On his inspiration for the project, Mad Dog Jones comments, “Fallen Gravity is about drifting into the unknown.
  • The Star Songs are created utilizing data sonification algorithms that convert astronomical images into audible music, mapping characteristics of the stars.
  • The custom Star Songs are integrated with the NFTs to celebrate and honor the duration of the International Space Station’s journey.
  • We’re proud to launch this mission, brought to life with our brilliant collaborators and partners, Mad Dog Jones, Artemis Music Entertainment, and Nifty Gateway.

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Patient, GMT, EDT

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.

Key Points: 
  • REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.
  • Anil Okay, Chief Commercial Officer, will be providing the update.
  • Information on how to access the webcast is posted on Alvotech’s investor website at https://investors.alvotech.com/events/event-details/market-update-2024-0... .
  • The webcast will be archived and available for replay for 90 days after the event.

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

Retrieved on: 
Wednesday, April 3, 2024
PIN, ADC, EDT, Therapy, Doctor of Philosophy

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT.

Key Points: 
  • LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT.
  • The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company’s novel exatecan-based antibody drug conjugate platform.
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

DIGITAL ALLY, INC ANNOUNCES 2023 OPERATING RESULTS

Retrieved on: 
Tuesday, April 2, 2024
Agreement, Social media, Health care, Sale, Business analyst, Closing, Note, Marketing, Moshing, Form, Heartland Stampede Music Festival, Prospectus, George M. Steinbrenner Field, Kustom, Plan, Country, News, Acquisition, Senior, Suite, Security, Brickell Avenue, Security agreement, Operating cost, EDT, Sub, The Borrowers, Finance Secretary (India), Traction, Music, ID, Patent, DGLY, Cryptocurrency

LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.

Key Points: 
  • LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.
  • Operating losses for the year ended December 31, 2023 and 2022 were $22,240,553 and $29,733,258, respectively, a decrease of $7,492,705 (25%).
  • Operating loss as a percentage of revenues improved to 78% in 2023 from 80% in 2022.
  • The Company will host an investor conference call at 11:15 a.m. EDT on Tuesday, April 2, 2023, to discuss its 2023 financial results, corporate and individual subsidiary outlook, and previously announced corporate separation.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Retrieved on: 
Tuesday, April 2, 2024
Disease, Macular edema, NIU, Paratriathlon, Arm, Rule, Safety, Risk, Webcast, Inflammation, Patient, NEPTUNE, EDT, Master of Science, Haze, Prednisone, Visual acuity, Therapy, Sumitomo Pharma, Calendar, Share repurchase, JAK, Visual impairment, Physician, Hand, Pediatrics, Pharmaceutical industry

We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.

Key Points: 
  • We are also pleased to announce our authorized share repurchase program, and our agreed repurchase of all shares owned by Sumitomo Pharma.
  • The NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily.
  • All week 24 secondary efficacy endpoints, including haze grades, visual acuity, and macular thickness, were also positive and dose responsive.
  • The presentation and webcast details are also available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Patient, Itch, Conference, EDT, Therapy

STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

Key Points: 
  • STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
  • A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.

Cue Biopharma to Host Business Update Call and Webcast

Retrieved on: 
Tuesday, April 2, 2024
EDT, Ono Pharmaceutical

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT.

Key Points: 
  • BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT.
  • Live and archived versions of the event can be accessed via the Company’s website .
  • The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.
  • Monday, April 8 at 4:30 p.m. EDT